aTyr Pharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.6418
- Today's High:
- $1.69
- Open Price:
- $1.65
- 52W Low:
- $1.555
- 52W High:
- $3.65
- Prev. Close:
- $1.66
- Volume:
- 123228
Company Statistics
- Market Cap.:
- $94.70 million
- Book Value:
- 1.862
- Revenue TTM:
- $10.39 million
- Operating Margin TTM:
- -460.11%
- Gross Profit TTM:
- $-32422000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -26.11%
- Return on Equity TTM:
- -46.82%
Company Profile
aTyr Pharma Inc had its IPO on 2015-05-07 under the ticker symbol LIFE.
The company operates in the Healthcare sector and Biotechnology industry. aTyr Pharma Inc has a staff strength of 65 employees.
Stock update
Shares of aTyr Pharma Inc opened at $1.65 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.64 - $1.69, and closed at $1.65.
This is a -0.6% slip from the previous day's closing price.
A total volume of 123,228 shares were traded at the close of the day’s session.
In the last one week, shares of aTyr Pharma Inc have slipped by -2.94%.
aTyr Pharma Inc's Key Ratios
aTyr Pharma Inc has a market cap of $94.70 million, indicating a price to book ratio of 0.8306 and a price to sales ratio of 37.7611.
In the last 12-months aTyr Pharma Inc’s revenue was $10.39 million with a gross profit of $-32422000 and an EBITDA of $-47458000. The EBITDA ratio measures aTyr Pharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, aTyr Pharma Inc’s operating margin was -460.11% while its return on assets stood at -26.11% with a return of equity of -46.82%.
In Q2, aTyr Pharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 1325.7%.
aTyr Pharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.22 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into aTyr Pharma Inc’s profitability.
aTyr Pharma Inc stock is trading at a EV to sales ratio of 12.4671 and a EV to EBITDA ratio of 0.1008. Its price to sales ratio in the trailing 12-months stood at 37.7611.
aTyr Pharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $132.75 million
- Total Liabilities
- $12.37 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $2.40 million
- Dividend Payout Ratio
- 0%
aTyr Pharma Inc ended 2024 with $132.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $132.75 million while shareholder equity stood at $106.24 million.
aTyr Pharma Inc ended 2024 with $0 in deferred long-term liabilities, $12.37 million in other current liabilities, 57000.00 in common stock, $-441923000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $12.31 million and cash and short-term investments were $108.58 million. The company’s total short-term debt was $1,064,000 while long-term debt stood at $0.
aTyr Pharma Inc’s total current assets stands at $114.43 million while long-term investments were $0 and short-term investments were $96.27 million. Its net receivables were $1.29 million compared to accounts payable of $516000.00 and inventory worth $-96268000.00.
In 2024, aTyr Pharma Inc's operating cash flow was $0 while its capital expenditure stood at $2.40 million.
Comparatively, aTyr Pharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.65
- 52-Week High
- $3.65
- 52-Week Low
- $1.555
- Analyst Target Price
- $21.33
aTyr Pharma Inc stock is currently trading at $1.65 per share. It touched a 52-week high of $3.65 and a 52-week low of $3.65. Analysts tracking the stock have a 12-month average target price of $21.33.
Its 50-day moving average was $1.91 and 200-day moving average was $2.11 The short ratio stood at 1.36 indicating a short percent outstanding of 0%.
Around 985.6% of the company’s stock are held by insiders while 6504.6% are held by institutions.
Frequently Asked Questions About aTyr Pharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.